AcelRx to host a panel discussion on current anticoagulant use in dialysis


AcelRx Pharmaceuticals have announced that they will be hosting a key opinion leader (KOL) panel discussion virtually to explore its lead candidate Niyad for use as an anticoagulant in dialysis circuits.

The panel, which is taking place on 6 December 2023 at ET/8am PT, will include thought-leaders from both nephrology and critical care disciplines—Laurence Busse (Emory University School of Medicine, Atlanta, USA) and David W Boldt (UCLA Medical Center, Los Angeles, USA)—both of whom are also co-authors on a recent market research manuscript that reports current problems with anticoagulants when used in dialysis circuits.

They will also be discussing the study protocol for the upcoming Nafamostat Efficacy in Phase 3 Registrational Continuous Renal Replacement Therapy (NEPHRO CRRT) study, which will compare a placebo to Niyad for use in dialysis circuit anticoagulation, and is planned to begin later this year.

For further information or to register for this virtual event, click here.


Please enter your comment!
Please enter your name here